Cytokine-induced CEACAM1 expression on keratinocytes is characteristic for psoriatic skin and contributes to a prolonged lifespan of neutrophils

Journal of Investigative Dermatology, 129(3):671-81


Inserm, U844, Montpellier, France.
Institut Universitaire de Recherche Clinique, Montpellier, France.
Bioalternatives, Gençay, France.
Inserm U564, Angers, France.
Service de Dermatologie, CHU St. Eloi, Montpellier, France.
EA 4331, Université de Poitiers, CHU de Poitiers, France


Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) is a cell-surface glycoprotein, belonging to the carcinoembryonic antigen family, expressed by human neutrophils, epithelial cells, activated T and NK cells. CEACAM1 is expressed as a cell-surface molecule with different isoforms or can be secreted as a soluble protein.
Here, we show that keratinocytes in the outer epidermal layer of psoriatic skin express CEACAM1, unlike those in healthy skin or in cutaneous lesions of patients with atopic or nummular dermatitis. Stimulation of primary human keratinocytes or in vitro reconstituted epidermis with culture supernatants of activated psoriatic lesion-infiltrating T cells, IFN-gamma or oncostatin M, but not IL-17, induced the expression of transcripts for the CEACAM1-long and -short isoforms and cell-surface CEACAM1, whereas soluble CEACAM1 was not produced. The uppermost layers of the epidermis in psoriatic lesions also contain neutrophils, a cell type with inflammatory and antimicrobial properties. Coculture of CEACAM1-expressing keratinocytes or CHO transfectants with neutrophils delayed spontaneous apoptosis of the latter cells.
These results show that cytokine-induced cell-surface expression of CEACAM1 by keratinocytes in the context of a psoriatic environment might contribute to the persistence of neutrophils and thus to ongoing inflammation and the decreased propensity for skin infection, typical for patients with psoriasis.

© 2009 The Society for Investigative Dermatology.

KEYWORDS: Psoriasis; Keratinocyte; Cytokine; CEACAM1

Check out Bioalternatives’ updates and experience new testing ideas

  • The legal basis for the processing is consent. Your e-mail address will only be communicated to the following recipients: the departments concerned and authorised by QIMA LIFE SCIENCE. This data is kept for as long as you are registered to the newsletter.

    You can access your data, rectify it, request its deletion or exercise your right to limit the processing of your data, withdraw your consent to the processing of your data at any time, oppose the processing of your data and you have a right to the portability of your data.

    Visit for more information on your rights.
    You can exercise all your rights using the following linkGestion des droits or by writing to If you feel, after contacting us, that your "Informatique et Libertés" rights are not being respected, you can submit a complaint to the CNIL.

  • The information collected on this form is recorded in a file used by QIMA Life Sciences to send you its newsletter.

  • Bioassays, models and services
  • Posts and publications
  • Events